BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18931841)

  • 1. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Morita S; Suganuma N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):362-72. PubMed ID: 18931841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
    Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
    Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Fukasawa I; Inaba N; Suganuma N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1439-48. PubMed ID: 18418592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT.
    Kitajima K; Murakami K; Yamasaki E; Domeki Y; Tsubaki M; Sunagawa M; Kaji Y; Suganuma N; Sugimura K
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1388-96. PubMed ID: 19370346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
    Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
    Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
    Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
    Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
    Nasu K; Abe W; Takai N; Tomonari K; Narahara H
    Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.
    Sironi S; Picchio M; Landoni C; Galimberti S; Signorelli M; Bettinardi V; Perego P; Mangioni C; Messa C; Fazio F
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):472-9. PubMed ID: 17106701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
    Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma.
    Yang ZY; Hu SL; Shi W; Zhu BL; Xu JY; Zhang YJ
    Nucl Med Commun; 2011 Nov; 32(11):1018-25. PubMed ID: 21956489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
    Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
    Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
    Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
    J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.
    Kitajima K; Suzuki K; Nakamoto Y; Onishi Y; Sakamoto S; Senda M; Kita M; Sugimura K
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1490-8. PubMed ID: 20386901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.